Oridonin promotes Fbw7-mediated turnover of c-Myc
Introduction
The protein c-Myc is a helix-loop-helix leucine zipper transcription factor that plays essential roles in cell growth, proliferation and apoptosis. Several Given its importance, c-Myc is tightly regulated at different biological levels, including F-box and WD repeat domain-containing 7 (Fbw7)-mediated post-translational regulation (6, 7) .
However, the deregulation of c-Myc has been observed in a wide range of human cancers, particularly leukemias and lymphomas, due to gene amplification, translocation, transactivation, or increased protein stability. Deregulated c-Myc increases genomic instability, blocks differentiation, and is able to induce lymphoid and myeloid neoplasia, making it an attractive target for cancer treatment (8) (9) (10) .
Various strategies aimed at targeting c-Myc for cancer treatment are under investigation, including the use of antisense oligonucleotides, siRNAs, small molecules and natural compounds (8, (10) (11) (12) . Among these approaches, natural compounds have received particular attention in recent years due to their potent anti-cancer activities and relative safety. For example, it was recently shown that ascofuranone and curcumin, both as natural compounds, target c-Myc and exhibit anti-cancer activities (11, 12) . However, the mechanisms by which natural compounds target c-Myc still need to be investigated. Oridonin is a natural diterpenoid compound (Fig. 1A ) that can be isolated from the Chinese medicinal herb Rabdosia rubescens and other plants in the genus Isodon, which are traditionally used in China and Japan for the treatment of various human diseases (13, 14) . Oridonin exhibits pro-apoptotic activity against a variety of cancer cells, including those of hematological malignancies, and shows no obvious side effects in murine models (15, 16) . Although several proteins, including caspase-3, ERK, P53, Bax/Bcl-xL, AML-ETO and NF-κB, have been found to be involved in the anti-cancer activity of oridonin (16) (17) (18) (19) , the underlying mechanisms remain largely unknown, and further mechanistic studies are needed to provide evidence supporting the use of oridonin as a drug for cancer treatment.
To gain a deeper understanding of the molecular action of oridonin, we profiled miRNA expression in K562 cells in the absence or presence of oridonin and scored transcription factors reported to regulate the differentially expressed miRNAs, finally confirming that one of the miRNA regulators, c-Myc, was a molecular target of oridonin in vitro and in vivo. This observation is supported by a previous report that oridonin treatment decreased c-Myc expression in K562 cells (20) . We then explored the mechanism by which oridonin targets c-Myc and revealed that oridonin activates the E3 ubiquitin ligase Fbw7 and the GSK-3 kinase, which accelerates the ubiquitin-proteasome-dependent degradation of c-Myc and results in the apoptosis of K562 cells and a delay of tumor growth in a K562 xenograft model. Our findings provide molecular evidence supporting the use of oridonin as an effective Fbw7 activator, and therefore, a c-Myc targeting agent, in the treatment of c-Myc-overexpressing hematological malignancies or other cancers. 
Materials and Methods

Reagents
Oridonin (Kangrun Pharmaceutical, Hangzhou, China), MG-132 (Calbiochem) and cycloheximide (CHX; Beyotime) were dissolved in DMSO to make stock solutions and freshly used at concentrations of 20 μM, 10 μM and 50 μg/mL, respectively, unless otherwise specified.
The final concentrations of DMSO were kept below 0.1% in all cell cultures.
Cell lines and transfection
The K562 and HL60 cell lines were kindly provided by Dr. Shi-Mei Zhuang (Sun Yat-sen University). The B16BL6 cell line was purchased from KeyGEN Biotech. Other cell lines were obtained from the cell bank of Chinese Academy of Sciences (Shanghai, China). The K562 cell line was authenticated based on BCR-ABL expression and sequencing within the past 12 months, whereas other cell lines were not authenticated by the authors. All transient transfections of plasmids and siRNAs were performed using the Neon transfection system (Life Technologies). All siRNAs were purchased from GenePharma and transfected at a final concentration of 50 nM. Sequences for siRNAs are as follows:
Negative control: 5'-UUCUCCGAACGUGUCACGU-(dT) 2 -3'. Cells were cultured in 96-well cell culture plates and treated the next day as indicated. Cell viability was evaluated using MTT assays (Promega).
Cell growth, proliferation and apoptosis assays
Cell proliferation was assessed using soft agar assays. Briefly, 2000 cells from different treatments were mixed with a 0.35% gel (Sigma) and seeded over a 0.6% bottom gel. The colonies contained more than 50 cells were counted and photographed under a DM LB2 microscope (Leica) 7 days later.
Apoptosis was analyzed with a FACSCalibur flow cytometer (BD Biosciences) immediately after cells were FITC-Annexin V/PI double-stained. The data were analyzed using FlowJo software (Treestar).
miRNA expression profiling
The miRNA expression arrays including 235 human-specific miRNA probes and 8 control probes were generated as previously described (21) . A 22-nt oligonucleotide with a sequence complementary to a spotted control was added to the small RNA (12-28 nt) sample as a reference for normalization. The gel-purified small RNAs were dephosphorylated, radiolabeled and hybridized to membranes. Signals were visualized using a Typhoon 8600 imager (GE Healthcare) and quantified using ImageMaster TotalLab V2.00 (GE Healthcare).
RNA expression analysis
Northern blot detection of mature miRNAs and pre-miRNAs was performed according to the Bartel lab protocol (http://web.wi.mit.edu/bartel/pub/protocols.html).
For semiquantitative RT-PCR, 2 μg of total RNA was used for cDNA synthesis. For Supplementary Table S1 .
Western blot analysis
Cells were lysed as described (22) . Equal amounts of protein were loaded and separated by SDS-PAGE, transferred to polyvinylidene fluoride membranes, and detected by immunoblotting using the SuperECL Plus Detection Reagent (Applygen) or the ECL Advance Detection Kit (GE Healthcare). GAPDH was used as a loading control. See Supplementary   Table S2 for information regarding the antibodies used.
Immunoprecipitations (IP)
Cells were lysed with IP lysis buffer (Beyotime) at 6x10 6 cells/mL for control samples and 
Expression plasmids
The cDNAs of FLAG-tagged The data shown represent the mean of three independent experiments (three replicates each).
The error bars indicate the SDs. Statistical differences were assessed using the Student's t test. P <0.05 was considered statistically significant. 
Results
Oridonin exhibits anti-cancer activity against K562 cells both in vitro and in vivo
We first investigated the in vitro effects of oridonin in K562 cells. Oridonin inhibited cell growth in a concentration-and time-dependent manner, with an IC 50 of 14.6 μM after a 24-hour treatment (Fig. 1A) . The colony-forming ability of K562 cells in soft agar was also markedly impaired ( 
miRNA expression profiling reveals that c-Myc is a target of oridonin
To explore the anti-cancer mechanisms of oridonin, we generated oligonucleotide DNA arrays for detection of miRNA expression, because accumulating evidence suggested that miRNA expression profiling could be used as a tool to understand responses to therapy in human cancers (24, 25) . We found that 16 miRNAs were upregulated and 12 miRNAs were downregulated by more than two-fold upon oridonin treatment, primarily representing the let-7 miRNA family and the miR-17-92 paralogous clusters (including the miR-17-92 cluster, miR-106a-363 cluster and miR-106b-25 cluster), respectively ( Fig. 2A) Fig. S1A ). Notably, the miRNA precursors (pre-miRNAs) of the members of the miR-17-92 paralogous clusters were also dramatically decreased by oridonin (Fig. 2B) , which is suggestive of regulation upstream of pre-miRNA processing, likely at the transcriptional level. Accordingly, we began to search for transcription factors that were affected by oridonin and hence, resulted in the differential expression of the miRNAs mentioned above. As described in the Supplementary Materials and Methods, we scored transcription factors that had been reported to regulate any oridonin-induced differentially expressed miRNA and listed in Supplementary   Table S3 Table S3 ). c-Myc protein expression was also positively correlated with oridonin activity in these cell lines with an r value of 0.452 (P <0.01) or a rho value of 0.367 (P <0.05). This significant positive correlation was also experimentally verified in 10 cell lines of leukemia and solid tumor origin (Fig. 2C) .
Overall, these data suggest that c-Myc is a potential molecular target of oridonin and that the activity of oridonin is highly correlated with c-Myc expression. 
Oridonin decreases c-Myc expression in vitro and in vivo
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To determine the impact of oridonin on c-Myc, K562 cells were treated with oridonin, and western blots were performed. As shown in Fig. 3A and 3D , oridonin decreased c-Myc protein levels in a time-and concentration-dependent manner. In addition, K562 xenograft tumors treated with oridonin showed remarkably reduced levels of c-Myc compared with the control group (Fig. 3B) . The oridonin-induced reduction of c-Myc resulted in the altered expression of certain miRNA primary transcripts (pri-miRNAs) (Fig. 3C and Supplementary Fig. S1B ), all of which were reported to be transcriptional targets of c-Myc (3, 26) . These changes in pri-miRNA levels were similar to but more significant than those caused by c-Myc siRNA (Fig. 3C) .
Overall, these results demonstrate that oridonin targets c-Myc in vitro and in vivo, by reducing c-Myc protein levels and thereby impairing its transcriptional activity.
We next explored the correlation between oridonin potency and the reduction of c-Myc in four leukemia and lymphoma cell lines including K562, KU812, HL-60 and Daudi. In all of these cell lines, the cell growth was inhibited by oridonin in a concentration-dependent manner (Fig. 3D) . Interestingly, the expression change of c-Myc was almost entirely consistent with the change in cell viability (Fig. 3D) , which further demonstrates that the reduction of c-Myc is correlated with the anti-cancer effects of oridonin and that c-Myc is an important target of oridonin.
Oridonin promotes the ubiquitin-proteasome dependent degradation of c-Myc
Given the importance of c-Myc in diverse cellular processes, we further explored the mechanisms by which c-Myc is regulated. RT-PCR showed that the c-myc mRNA level remained unchanged after oridonin treatment (Fig. 4A) , which was also confirmed by qRT-PCR 
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(data not shown) and suggested that oridonin did not affect the transcription or mRNA stability of c-myc. We also performed dual-luciferase assays to rule out the existence of oridonin-responsive elements within the 5'UTR or 3'UTR of c-myc that could affect the translation of c-myc mRNA (Supplementary Fig. S2A ). Thus, based on the above results, it appears unlikely that oridonin regulates c-Myc by affecting the synthesis of its mRNA or protein.
Previous studies have shown that the c-Myc protein has a very short half-life and is degraded through the ubiquitin-proteasome pathway. In the presence of oridonin, the half-life of c-Myc in K562 cells was further reduced, as observed with CHX chase assays ( (Fig. 4C) . When we used MG-132 to inhibit the 26S proteasome activity in K562 cells, the oridonin-induced downregulation of c-Myc was significantly antagonized (Fig. 4D) . Similar results were observed in KU812, HL60 and Daudi cells ( Supplementary Fig. S2B ). We therefore concluded that oridonin downregulated c-Myc by promoting its ubiquitin-proteasome dependent degradation rather than by decreasing its synthesis.
Oridonin activates the Fbw7 E3 ubiquitin ligase
The process of ubiquitination has been shown to require the consecutive action of an E1 ubiquitin-activating enzyme, an E2 ubiquitin-conjugating enzyme and an E3 ubiquitin ligase. substrate specificity (27) . To determine how oridonin affects the ubiquitination of c-Myc, we examined the protein expression levels of Fbw7, an E3 ubiquitin ligase shown to be responsible for the ubiquitin-mediated degradation of c-Myc (6, 7) and other oncogenes such as cyclin E (28, 29) and mTOR (30) . Oridonin treatment significantly increased the expression of Fbw7α and Fbw7γ in a time-dependent manner, which was accompanied by the remarkable downregulation of c-Myc, cyclin E and mTOR, among which the reduction of c-Myc was the most significant ( Fig. 5A and Supplementary Fig. S3A ). We also detected the expression of the deubiquitinating enzyme USP28, which could interact with Fbw7α and thereby antagonize the degradation of c-Myc (31). As shown in Fig. 5A , oridonin did not affect the expression of USP28. Additionally, we performed immunoprecipitations to assess the interaction of c-Myc with Fbw7. As expected, c-Myc-associated Fbw7 increased significantly in oridonin-treated cells (Fig. 5A ).
To further demonstrate the importance of Fbw7 in oridonin-induced c-Myc degradation, we utilized two T-cell acute lymphoblastic leukemia (T-ALL) cell lines, Jurkat and CCRF-CEM, which harbor an R505C and an R465C missense mutation in Fbw7, respectively (32, 33) . When exposed to oridonin, the decrease of c-Myc in these two cell lines was less evident than that in K562 (Fig. 5B) , implying that the abundance of functional Fbw7 affects the efficiency of oridonin-induced c-Myc degradation. Taken together, our results strongly indicate that oridonin promotes the degradation of c-Myc through the activation of the Fbw7 E3 ligase.
Oridonin activates GSK-3 and enhances the phosphorylation of c-Myc at T58
GSK-3 is an Fbw7 priming kinase that phosphorylates most known previously shown that the GSK-3-mediated phosphorylation of c-Myc T58 was needed for the efficient binding of c-Myc by Fbw7 (34, 35) . We investigated GSK-3 activity in K562 cells upon oridonin treatment. Phosphorylated/inactive GSK-3 decreased, whereas the total GSK-3 protein levels remained unchanged (Fig. 5C) , indicating the activation of GSK-3. Accordingly, T58-phosphorylated c-Myc increased significantly as expected (Fig. 5C ). When we transiently inhibited GSK-3 with either siRNA or LiCl (a selective GSK-3 inhibitor), the oridonin-induced degradation of c-Myc was somewhat delayed (Fig. 5D) , suggesting a dependence on GSK-3 in this process.
The Fbw7-c-Myc pathway contributes to the anti-cancer activities of oridonin
Because oridonin was able to upregulate Fbw7, we evaluated the effects of Fbw7 overexpression in K562 cells. As shown in Fig. 6A , the overexpression of the three isoforms of Fbw7 (α, β and γ) all decreased c-Myc levels, although to different extents. At the cellular level, Fbw7 remarkably inhibited the growth of K562 cells in culture medium and in soft agar (Fig.   6A ), and substantially increased the fraction of apoptotic cells as determined by FACS analysis (Fig. 6B) . The anti-cancer property of Fbw7 was comparable to that of c-Myc silencing ( Fig.   6A and 6B) except for a slighter effect on the anchorage independent growth in soft agar (Fig.   6A ). These results reveal that the forced expression of Fbw7 inhibits growth and induces apoptosis in K562 cells, which could also be achieved by silencing c-Myc expression. (Fig. 6C) . In addition, the overexpression of stable c-Myc that was mutated at both T58 and S62 (both within the CPD) and unable to be ubiquitinated partially conferred resistance to oridonin-induced apoptosis compared with the overexpression of wild-type c-Myc (Fig. 6C) . These results strongly suggest the importance of Fbw7 upregulation and c-Myc degradation in the pro-apoptotic ability of oridonin. 
Discussion
In this study, we explored the mechanism of action of the diterpenoid compound oridonin from a new point of view. We analyzed miRNA expression data in the context of oridonin treatment and determined that a transcriptional regulator of most of the differentially expressed miRNAs, c-Myc, was a molecular target of oridonin. By activating the E3 ubiquitin ligase Fbw7 and the GSK-3 kinase, oridonin induces the rapid turnover of c-Myc and the reprogramming of c-Myc-regulated miRNAs, resulting in growth inhibition and apoptosis.
These mechanisms are summarized in Fig. 6D .
Research indicates that c-Myc acts as a double-edged sword in cell-fate decisions because it can promote cell growth or induce apoptosis (36, 37) . Our results showed that inhibition of c-Myc expression led to severe cell death (Fig. 6B) , suggesting that the deregulated c-Myc in leukemia and lymphoma cells was oncogenic rather that tumor-suppressive. Due to its oncogenic properties, c-Myc has been investigated and shown to be an effective target for cancer therapy (8, 10, 38) 
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The mechanism underlying the oridonin-induced c-Myc downregulation was still unclear although the decrease of c-Myc by oridonin was also reported in prior work (20, 39) . It was previously shown that treatment of SW1116 colorectal cancer cells with 25 μM oridonin reduced c-myc transcription and protein levels after 24 hours or a longer period of time (39) .
However, our work showed that oridonin did not affect the mRNA level of c-myc in K562 cells after a 24-hour treatment but dramatically induced the degradation of c-Myc protein as early as 40 minutes. The rapid degradation of c-Myc was also observed in other malignant hematologic cell lines, including KU812, HL-60 and Daudi ( Supplementary Fig. S2B ). We demonstrated, for the first time, that a ubiquitin-proteasome-dependent pathway was involved in oridonin-induced c-Myc downregulation. There are two rate-limiting steps in proteasomal degradation: the specific modification of substrate proteins, such as phosphorylation, and the enzymatic attachment of ubiquitin to substrate proteins (40) . In this study, we showed that oridonin acts upon these two steps to achieve its most potent effect on c-Myc degradation in K562 cells (Fig.   6D ). However, we observed that the transient inhibition of GSK-3 could not fully antagonize the oridonin-induced degradation of c-Myc. This observation may suggest that the activation of GSK-3 was less important than the activation of Fbw7 in oridonin-induced c-Myc degradation, or that the residual kinase activity of GSK-3 was sufficient for the phosphorylation of c-Myc.
We also examined the phosphorylation levels of AKT, an upstream kinase of GSK3. Oridonin significantly reduced pAKT levels (data not shown), which was consistent with previous reports (41) and suggested that the downregulation of pAKT may be involved in the activities of oridonin.
The ubiquitin-proteasome system (UPS) plays a crucial role in fine-tuning the abundance of (27) . The deregulation of the UPS has been observed in many types of cancer, and studies targeting the UPS for cancer therapy are being conducted (27) . As a component of the UPS, Fbw7 ubiquitin ligase plays a vital role in cell fate decisions (35, 42) . It was recently shown that Fbw7 controlled the fate of hematopoietic stem cells (43) and affected the proliferation and lymphomagenesis of mouse T cells (44) rather than by affecting the expression of USP28. From this point of view, oridonin can be seen as an agonist of Fbw7, and as a result, has potential clinical implications. As to the mechanism underlying the Fbw7 activation, we found that the mRNA levels of Fbw7 were not affected by oridonin after a 2-hour treatment, whereas a 24-hour treatment did upregulate the mRNA levels of Fbw7β (data not shown), which might be mediated by p53 (50) . Further mechanistic studies are being conducted.
In summary, we demonstrated the potent anti-cancer activity of oridonin in vitro and in vivo and determined that the underlying mechanism involves the regulation of an E3 ligase-substrate pair (Fbw7-c-Myc). It appears that the exposure of leukemia and lymphoma cells to oridonin activates Fbw7 and GSK-3β, and in this way, effectively triggers the Fbw7-mediated ubiquitination and proteasome-dependent degradation of c-Myc, leading to growth inhibition and apoptosis. Our results also provide evidence for the use of miRNA expression profiling as a tool to understand the molecular mechanisms of drug actions by retracing the expression changes in upstream transcription factors. Additionally, it is possible that the altered expression of oncogenic miRNAs (e.g., the miR-17-92 cluster) and tumor-suppressor miRNAs (e.g., let-7a) caused by c-Myc downregulation accounts for the anti-cancer activity of oridonin. It will be valuable to identify and study the roles of the target proteins of these miRNAs as well as other c-Myc downstream genes in the context of oridonin treatment to better understand the anti-cancer activities of this natural compound.
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